Healthcare: Glaxo, Ligand Look For New Promacta Indication
The FDA may issue its decision this week regarding GlaxoSmithKline/Ligand’s supplemental New Drug Application (sNDA) for Promacta. A decision from the agency is expected by Nov. 24, Bloomberg Industries estimates.
Glaxo submitted regulatory filings in the U.S. and EU at the end of May. The application seeks to expand the drug’s label to include treatment of thrombocytopenia in – To continue reading click here.